Literature DB >> 7132406

Benefits of normothermic induction of blood cardioplegia in energy-depleted hearts, with maintenance of arrest by multidose cold blood cardioplegic infusions.

E R Rosenkranz, J Vinten-Johansen, G D Buckberg, F Okamoto, H Edwards, H Bugyi.   

Abstract

This study tests the hypothesis that warm induction of cardioplegia prior to prolonged maintenance by multidose infusions of cold blood cardioplegic solution would increase the tolerance of energy-depleted hearts to subsequent aortic clamping. Eighty percent depletion of subendocardial adenosine triphosphate (ATP) was produced in 30 dogs by 45 minutes of normothermic ischemia. This was followed either by unmodified blood reperfusion or 2 additional hours of aortic clamping with multidose cold blood cardioplegia. We compared a brief (5 minute) period of 37 degrees C cardioplegic induction to standard 4 degrees C blood cardioplegic induction to determine if warm induction would enhance metabolic and functional recovery. Warm cardioplegic induction resulted in more oxygen consumption than cold induction (16.9 versus 8.1 cc/100 gm), and lower levels of glucose-6-phosphate (G6P), suggesting better aerobic metabolism (0.97 versus 1.87 microM/gm wet weight). Prompt repletion of creatine phosphate (CP) occurred with warm and cold cardioplegic induction, although ATP levels levels remained low. Hearts undergoing ischemia and unmodified reperfusion consumed insufficient oxygen to meet basal metabolic needs during reperfusion (7 cc/100 gm below requirement) and recovered only 33% +/- 5% of control left ventricular performance. Better function occurred with cold cardioplegic induction (63% +/- 5%), and almost complete recovery (85% +/- 5%) occurred when warm induction of cardioplegia was used. We conclude that warm induction followed by prolonged cold multidose blood cardioplegic arrest enhances aerobic metabolism, results in normal left ventricular performance, and improves tolerance of aortic clamping in energy-depleted hearts.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7132406

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  7 in total

1.  Myocardial protection during surgical intervention for treatment of acute myocardial infarction.

Authors:  F Beyersdorf; G D Buckberg
Journal:  Tex Heart Inst J       Date:  1992

Review 2.  Lung inflammatory response syndrome after cardiac-operations and treatment of lornoxicam.

Authors:  Kosmas Tsakiridis; Andreas Mpakas; George Kesisis; Stamatis Arikas; Michael Argyriou; Stavros Siminelakis; Paul Zarogoulidis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Theodora Tsiouda; Eirini Sarika; Ioanna Katamoutou; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

3.  Reduction of oxidative stress does not affect recovery of myocardial function: warm continuous versus cold intermittent blood cardioplegia.

Authors:  B Biagioli; E Borrelli; M Maccherini; G Bellomo; G Lisi; P Giomarelli; G Sani; M Toscano
Journal:  Heart       Date:  1997-05       Impact factor: 5.994

Review 4.  Cardiac ischemia. Part II--Reperfusion and treatment.

Authors:  G A Langer; G D Buckberg; J H Tillisch
Journal:  West J Med       Date:  1987-07

5.  Myocardial oedema and ventricular function after cardioplegia with added mannitol.

Authors:  R Goto; H Tearle; D J Steward; P G Ashmore
Journal:  Can J Anaesth       Date:  1991-01       Impact factor: 5.063

Review 6.  Mechanisms of oxidative stress and myocardial protection during open-heart surgery.

Authors:  Nikolaos G Baikoussis; Nikolaos A Papakonstantinou; Chrysoula Verra; Georgios Kakouris; Maria Chounti; Panagiotis Hountis; Panagiotis Dedeilias; Michalis Argiriou
Journal:  Ann Card Anaesth       Date:  2015 Oct-Dec

Review 7.  Transplantation of Hearts Donated after Circulatory Death.

Authors:  Christopher W White; Simon J Messer; Stephen R Large; Jennifer Conway; Daniel H Kim; Demetrios J Kutsogiannis; Jayan Nagendran; Darren H Freed
Journal:  Front Cardiovasc Med       Date:  2018-02-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.